Summary
1.64
-0.08
(-4.65%)
06/05/2026
enGene Holdings Inc. (ENGN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -4.65 | -7.87 | -79.21 | -81.17 | -79.68 | -54.70 | 0.00 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | C+ |
| Recommended Rating | Sell |
| DCF | Neutral |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Neutral |
| P/E | Strong Sell |
| P/B | Neutral |
Earnings
| Trading Data | ||
| Close | 1.64 | |
| Open | 1.71 | |
| High | 1.74 | |
| Low | 1.61 | |
| Volume | 954,398 | |
| Change | -0.08 | |
| Change % | -4.65 | |
| Avg Volume (20 Days) | 2,862,486 | |
| Volume/Avg Volume (20 Days) Ratio | 0.33 | |
| 52 Week Range | 1.40 - 12.25 | |
| Price vs 52 Week High | -86.61% | |
| Price vs 52 Week Low | 17.14% | |
| Range | -4.09 | |
| Gap Up/Down | -0.06 | |
Profitibility | ||
| Market Capitalization (Mln) | 304 | |
| Revenue per share | 0.0000 | |
| Net Income per share | -1.8203 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -0.9010 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
06/04 10:00 EST - prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. ("Engene" or the "Company") (NASDAQ: ENGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. ("Engene" or the "Company") (NASDAQ: ENGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
05/29 08:49 EST - businesswire.com
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $ENGN--ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm.
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $ENGN--ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm.
05/09 14:21 EST - seekingalpha.com
enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript
enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript
enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript
enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript
05/08 19:06 EST - marketbeat.com
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain
enGene NASDAQ: ENGN reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain
enGene NASDAQ: ENGN reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.
05/07 15:35 EST - globenewswire.com
enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of enGene Therapeutics Inc. (NASDAQ: ENGN). The investigation focuses on enGene's executive officers and whether investor losses may be recovered under federal securities laws.
enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of enGene Therapeutics Inc. (NASDAQ: ENGN). The investigation focuses on enGene's executive officers and whether investor losses may be recovered under federal securities laws.
05/07 07:00 EST - businesswire.com
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported additional interim results from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid...
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported additional interim results from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid...
04/07 08:00 EST - businesswire.com
enGene Announces Name Change to enGene Therapeutics Inc.
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.”...
enGene Announces Name Change to enGene Therapeutics Inc.
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.”...
03/26 02:29 EST - defenseworld.net
enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Rating of “Moderate Buy” from Analysts
enGene Holdings Inc. (NASDAQ: ENGN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have...
enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Rating of “Moderate Buy” from Analysts
enGene Holdings Inc. (NASDAQ: ENGN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have...
03/17 02:32 EST - defenseworld.net
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference
Executives from enGene (NASDAQ: ENGN) provided an update on the company's detalimogene program in non-muscle invasive bladder cancer (NMIBC), discussing recent protocol changes, regulatory interactions, and commercial planning as the study advances. Protocol amendments and response-rate improvement...
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference
Executives from enGene (NASDAQ: ENGN) provided an update on the company's detalimogene program in non-muscle invasive bladder cancer (NMIBC), discussing recent protocol changes, regulatory interactions, and commercial planning as the study advances. Protocol amendments and response-rate improvement...
03/17 02:32 EST - defenseworld.net
enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update
enGene (NASDAQ: ENGN) Chief Executive Officer Ron Cooper used a presentation at the Citizens Life Sciences Conference to outline the company's approach to non-muscle invasive bladder cancer (NMIBC), emphasizing both the unmet need in the disease and the company's view that its investigational...
enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update
enGene (NASDAQ: ENGN) Chief Executive Officer Ron Cooper used a presentation at the Citizens Life Sciences Conference to outline the company's approach to non-muscle invasive bladder cancer (NMIBC), emphasizing both the unmet need in the disease and the company's view that its investigational...
03/12 18:26 EST - seekingalpha.com
enGene Holdings: Key Catalysts Incoming For 2026
enGene Holdings remains on track with a cautiously optimistic 'Buy' rating, supported by promising clinical data and strong financial positioning. ENGN's lead candidate, detalimogene voraplasmid, demonstrated a 63% complete response rate at 3 months in NMIBC, with favorable tolerability and pivotal...
enGene Holdings: Key Catalysts Incoming For 2026
enGene Holdings remains on track with a cautiously optimistic 'Buy' rating, supported by promising clinical data and strong financial positioning. ENGN's lead candidate, detalimogene voraplasmid, demonstrated a 63% complete response rate at 3 months in NMIBC, with favorable tolerability and pivotal...
03/10 16:40 EST - seekingalpha.com
enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
03/09 07:00 EST - businesswire.com
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2026, and provided a business update. “As data from...
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2026, and provided a business update. “As data from...
02/20 08:00 EST - businesswire.com
enGene to Participate in Upcoming Investor Conferences
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date:...
enGene to Participate in Upcoming Investor Conferences
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date:...
02/04 08:00 EST - businesswire.com
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech...
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech...
Market News
×
Loading news…